Tacrolimus: A new option in therapy-resistant chronic external otitis

Laryngoscope

Volumn 117, Issue 6, 2007, Pages 1046-1052

  Caffier, Philipp P ^a   Harth, Wolfgang ^a   Mayelzadeh, Babak ^a   Haupt, Heidemarie ^a   Sedlmaier, Benedikt ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chronic inflammation; External otitis; Immune modulation; Resistance to therapy; Tacrolimus

Indexed keywords

TACROLIMUS;

ADOLESCENT; ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CHILD; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE FREE INTERVAL; DISEASE SEVERITY; EXTERNAL AUDITORY CANAL; EXTERNAL OTITIS; FOLLOW UP; HEALING; HEAT SENSATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; SKIN BURNING SENSATION; SKIN PRURITUS; STATISTICAL SIGNIFICANCE; TOPICAL TREATMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CEREBROSPINAL FLUID OTORRHEA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; EARACHE; EDEMA; ERYTHEMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OTITIS EXTERNA; OTOSCOPY; PROSPECTIVE STUDIES; PRURITUS; TACROLIMUS; TREATMENT OUTCOME;

EID: 34249905470     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLG.0b013e31804b1aad     Document Type: Article

References (15)

1. Beers SL, Abramo TJ. Otitis externa review. Pediatr Emerg Care 2004;20:250-256.
2. Yariktas M, Yildirim M, Doner F, Baysal V, Dogru H. Allergic contact dermatitis prevalence in patients with eczematous external otitis. Asian Pac J Allergy Immunol 2004;22:7-10.
3. Roland PS, Pien FD, Schultz CC, et al. Efficacy and safety of topical ciprofloxacin/dexamethasone versus neomycin/polymyxin B/hydrocortisone for otitis externa. Curr Med Res Opin 2004;20:1175-1183.
4. Osguthorpe JD, Nielsen DR. Otitis externa: review and clinical update. Am Fam Physician 2006;74:1510-1516.
5. Alomar A, Berth-Jones J, Bos JD, et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004;151(Suppl 70):3-27.
6. Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs 2005;65:827-858.
7. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004;53:2079-2086.
8. Becker BC, Tos M. Postinflammatory acquired atresia of the external auditory canal: treatment and results of surgery over 27 years. Laryngoscope 1998;108:903-907.
9. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 1995;17:584-591.
10. Reynolds NJ, Al Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol 2002;27:555-561.
11. Fleischer AB, Jr., Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002;47:562-570.
12. Schuller E, Oppel T, Bornhovd E, Wetzel S, Wollenberg A. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol 2004;114:137-143.
13. Katoh N, Hirano S, Yasuno H, Kishimoto S. Effects of tacrolimus ointment on facial eruption, itch, and scratching in patients with atopic dermatitis. J Dermatol 2004;31:194-199.
14. Spergel JM, Leung DY. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep 2006;6:270-274.
15. Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005;124:695-699.